Today's FierceBiotech Research

Arsalan Arif, Fierce Life Sciences publisher

Earlier today, we inadvertently sent you the current issue of FierceBiotech Research, the weekly R&D sister publication to FierceBiotech. We apologize for the error, and you will not be sent FierceBiotech Research in the future. 

If you'd prefer to opt-in and begin a free subscription to FierceBiotech Research, please click here. 

Arsalan Arif
Publisher, Fierce Life Sciences
Email | Follow me on Twitter

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”